Foresite Capital Management II’s Aimmune Therapeutics AIMT Stock Holding History

Foresite Capital Management II’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,605,499	Closed	-$54.6M	–	6
2019 Q3	$54.6M	Sell	2,605,499 -121,069	-4%	-$2.47M	11.53%	2
2019 Q2	$56.8M	Hold	2,726,568	–	–	31.92%	1
2019 Q1	$60.9M	Sell	2,726,568 -242,081	-8%	-$5.7M	27.51%	2
2018 Q4	$71M	Sell	2,968,649 -332,148	-10%	-$8.59M	37.63%	1
2018 Q3	$90M	Sell	3,300,797 -55,952	-2%	-$1.58M	33.33%	2
2018 Q2	$90.3M	Buy	3,356,749 +36,804	+1%	+$1.13M	31.8%	2
2018 Q1	$106M	Buy	3,319,945 +219,799	+7%	+$7.73M	35.15%	1
2017 Q4	$117M	Sell	3,100,146 -720,316	-19%	-$23.2M	40.96%	1
2017 Q3	$94.7M	Sell	3,820,462 -172,055	-4%	-$3.71M	38.39%	1
2017 Q2	$82.1M	Hold	3,992,517	–	–	37.61%	2
2017 Q1	$86.8M	Buy	3,992,517 +156,687	+4%	+$3.21M	37.22%	1
2016 Q4	$78.4M	Sell	3,835,830 -132,070	-3%	-$2.7M	39.37%	1
2016 Q3	$59.5M	Hold	3,967,900	–	–	28.42%	2
2016 Q2	$42.9M	Sell	3,967,900 -120,000	-3%	-$1.63M	29.35%	1
2016 Q1	$55.4M	Hold	4,087,900	–	–	27.13%	1
2015 Q4	$75.4M	Hold	4,087,900	–	–	25.29%	1
2015 Q3	$104M	Buy	+4,087,900	New	+$95.6M	31.43%	1

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Foresite Capital Management II's AIMT Position: Q4 2019 in Review

Foresite Capital Management II sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 2,605,499 shares — an estimated $54.6M sold.

Foresite Capital Management II first reported a position in AIMT in Q3 2015 and held it in 17 quarters. The position peaked at $117M in Q4 2017. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

Foresite Capital Management II reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
Foresite Capital Management II sold 2,605,499 Aimmune Therapeutics shares in Q4 2019, an estimated $54.6M.
Foresite Capital Management II first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 17 quarters.
Foresite Capital Management II's Aimmune Therapeutics position peaked at $117M in Q4 2017.
155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Foresite Capital Management II's 13F filing for Q4 2019, filed 5 Feb 2020.